Brandon Sheffield, Diagnostic and Molecular Pathologist at William Osler Health System, shared on LinkedIn:

“Great new resource for pathologists and oncologists!

A lot has changed in gastric cancer, we have a lot of new therapies to offer. Pathologists are playing a big part here with Claudin18 becoming the latest IHC biomarker coming into play for precision medicine in gastric cancer patients.

Read on to see some helpful recommendations from Canadian pathologists and oncologists.”

Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma

Authors: Christine Brezden-Masley, Pierre O. Fiset, Carol C. CheungThomas Arnason, Justin Bateman, Martin Borduas, Gertruda Evaristo, Diana N. Ionescu, Howard J. Lim, Brandon S. Sheffield, Sara V. Soldera, Catherine J. Streutker

Brandon Sheffield: Canadian Expert Consensus on Predictive Biomarker Testing in Gastric and GEJ Adenocarcinoma